Ibogaine ECG Requirements: Pre-Infusion Cardiac Checklist

Definition

Definition: Ibogaine ECG requirements are the cardiac screening and monitoring steps a physician-supervised program should complete before and during IV ibogaine infusion—psychoactive intravenous ibogaine in a medical infusion setting (consult → cardiac screening → monitored infusion → integration). Because ibogaine can prolong the QTc interval and raise arrhythmia risk, baseline ECG/EKG, electrolyte review, medication interaction screening, and continuous telemetry during the high-risk window are non-negotiable. Evidence gap: Key QTc signals in the literature (e.g., Knuijver et al., *Addiction* 2021) come from oral ibogaine HCl series; Cherian et al., *Nature Medicine* 2024 used oral ibogaine with IV magnesium support—not psychoactive IV proof. Oral cardiac lessons still inform IV-protocol diligence. Ibogaine is U.S. Schedule I and not approved for any indication.

Short answer

Ibogaine ECG requirements typically include a pre-care ECG with QTc review, electrolyte labs, medication screening for QT-prolonging drugs, and continuous cardiac monitoring during IV ibogaine infusion under physician supervision. Much published QTc evidence reflects oral ibogaine HCl, often with support IV such as magnesium—not automatic proof that psychoactive IV dosing is equivalent. It is not approved for any indication.

Why ECG is the centerpiece of ibogaine safety education

Searchers looking for ibogaine ECG requirements are usually trying to answer a practical question: *What cardiac workup should exist before anyone receives ibogaine?* On this site, that question sits under true IV ibogaine infusion care—not spa branding. To see why the threshold matters, read how much ibogaine prolongs QTc in a monitored study.

Cardiac risk is not theoretical marketing. Observational oral-route work (Knuijver et al., *Addiction*, 2021) reported clinically relevant QTc prolongation after oral ibogaine HCl in opioid-dependent participants. That study did not observe torsades in its small sample, but the safety implication is clear: screen, monitor, be ready to stop.

Primary safety home: /safety-and-screening. Related long-tail: /blog/is-ibogaine-safe-screening-cardiac-risk. Entity definition: /what-is-ibogaine-infusion.

Pre-infusion checklist (patient-facing education)

Use this as a discussion checklist with clinicians—not a DIY clearance tool and not a substitute for individualized medical judgment.

A. History & risk factors (before scheduling)

• [ ] Full cardiac history (MI, heart failure, congenital long QT, arrhythmias, syncope, unexplained collapse)
• [ ] Family history of sudden cardiac death / known long-QT syndromes when available
• [ ] Substance-use timeline (opioids including fentanyl, stimulants, alcohol, benzos)
• [ ] Psychiatric status and prior adverse reactions to dissociatives/psychedelics
• [ ] Complete medication & supplement list (including OTC and “herbal detox”)
• [ ] Explicit screen for QT-prolonging and interacting drugs

B. Diagnostics (pre-care)

• [ ] ECG/EKG with documented QTc (method and rate correction noted)
• [ ] Repeat ECG if clinically indicated closer to infusion day
• [ ] Electrolytes with emphasis on magnesium and potassium
• [ ] Additional labs as indicated (liver/kidney, etc.)
• [ ] Written go / delay / cancel criteria tied to QTc and labs

C. Day-of infusion readiness

• [ ] Physician (MD/DO) oversight plan for infusion + peak-risk window
• [ ] Continuous ECG/telemetry planned (duration stated in writing)
• [ ] IV access for support meds (fluids, electrolytes, antiemetics, emergencies) labeled separately from psychoactive IV ibogaine
• [ ] Crash-cart / ACLS-capable staffing and hospital transfer plan
• [ ] Consent that names cardiac arrhythmia risk and Schedule I / not approved for any indication status

D. After the acute window

• [ ] Observation period defined (hours to days as clinically appropriate)
• [ ] Criteria for extended monitoring
• [ ] Integration / aftercare plan (not a substitute for cardiac follow-up)
• [ ] Instructions for urgent symptoms (palpitations, syncope, chest pain)—seek emergency care

Journey overview: /how-it-works. Package expectations: /blog/ibogaine-treatment-package.

Support IV vs psychoactive IV on the checklist

Accuracy rule: Citing Cherian 2024’s IV magnesium does not mean a clinic studied or proved psychoactive IV ibogaine. See /blog/stanford-ibogaine-mistic and /blog/ibogaine-oral-vs-iv.

What “pass / fail” conversations often include

Clinicians—not blog checklists—decide fitness. Educationally, programs should be able to explain:

1. How baseline QTc informs delay/cancel decisions
2. How electrolyte correction is planned before dosing when needed
3. Which medications will be held or reviewed for QT risk
4. How long continuous telemetry lasts
5. What happens if QTc rises during monitoring

If a vendor says ECG is “optional if you feel healthy,” treat that as a red flag (/blog/cheap-ibogaine-clinic-red-flags, /blog/how-to-choose-an-ibogaine-clinic).

Oral literature still teaches IV-protocol ECG diligence

Bottom line: Sparse controlled IV-psychoactive evidence is not a reason to skip ECG. It is a reason to be more conservative and transparent.

Non-cardiac items that still belong beside the ECG checklist

Side-effect and safety education is broader than ECG alone (/blog/ibogaine-side-effects):

• Nausea/vomiting and aspiration risk management
• Ataxia / fall risk during and after the session
• Prolonged psychoactive intensity and observation staffing
• Polysubstance withdrawal complexity (especially opioids)

Condition context without cure claims: /ibogaine-for-addiction, /ibogaine-for-depression, /ibogaine-for-ptsd.

Legal note next to medical checklists (not legal advice)

Ibogaine is Schedule I in the United States (21 CFR 1308.11) and not approved for any indication. Completing an ECG checklist does not create legality or U.S. regulatory status. See /blog/is-ibogaine-legal-us.

Next steps

Download this page’s checklist mindset into your consult notes, then request a confidential screening consult if you want to discuss whether medical criteria may fit. Always pair commercial interest with /safety-and-screening. Next step: /apply. Cost context: /blog/cost-of-ibogaine-treatment.

FAQ

What ECG is required before ibogaine? A physician-directed baseline ECG/EKG with QTc assessment is a core pre-care expectation, often with electrolytes and medication review. Exact orders are individualized.

Do I need continuous monitoring during IV ibogaine infusion? Yes—continuous ECG/telemetry during the high-risk window is a medical non-negotiable for serious programs, alongside emergency readiness.

Are published QTc findings from IV or oral ibogaine? Key cited findings such as Knuijver 2021 are **oral**. They still motivate ECG discipline for IV protocols.

Does IV magnesium replace the need for ECG? No. Electrolyte support is not a substitute for ECG screening and continuous monitoring.

Can a normal ECG guarantee safety? No test eliminates all risk. ECG is necessary diligence, not a guarantee.

What if my QTc is prolonged at baseline? That is a clinical stop/delay conversation with a qualified physician—not something to override for travel timelines.

Where is the full safety page? /safety-and-screening and /faq.

Is ibogaine approved for medical use if screening is thorough? No. Screening quality does not equal regulatory approval. U.S. Schedule I status remains (/blog/is-ibogaine-legal-us).

Medical disclaimer

Educational checklist only—not a medical clearance protocol, diagnosis, or treatment plan. Ibogaine is not approved for any indication and carries serious cardiac risks including arrhythmia. Do not self-administer. Final go/no-go decisions belong to licensed clinicians. Next steps: /safety-and-screening, then /apply.

Sources (selected)

1. Knuijver T. et al. *Addiction*. 2021 — oral ibogaine HCl; QTc / cardiac observational findings.
2. Cherian K.N. et al. *Nature Medicine*. 2024 — open-label oral ibogaine + IV magnesium; not IV-psychoactive proof; RCTs needed.
3. Mosca A. et al. *Current Neuropharmacology* — systematic review; limited RCTs; cardiotoxicity concerns.
4. 21 CFR 1308.11 — ibogaine Schedule I (United States).